Sector News

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

April 10, 2021
Life sciences

That’s why its new strategic plan includes doubling the number of Black and Latinx directors and officers in leadership positions by 2025 and committing $1 billion in spending with diverse suppliers.

Genentech’s formalized plan comes in part as a response to a survey the company ran last year investigating health inequities. One of the key findings? One in three people in marginalized communities avoid participating in clinical trials, shun vaccines and reject testing because they don’t trust the industry.

Calling the findings “unacceptable,” Quita Highsmith, Genentech’s vice president and chief diversity officer, said bridges must be built to make patients “feel valued, respected, and understood. We must give them reasons to believe in the healthcare system. Until then, health equity cannot be achieved.”

Genentech knows from experience that concerted efforts around diversity can work. Its 10-year commitment to increasing the number of women in leadership roles and creating gender pay equity practices has resulted in 43% officer level representation by women, up from 24% in 2010.

Pay is essentially equal today at the pharma, where women make 99.6 cents for every dollar men earn—and also holds true for employees of color, who earn 99.5 cents for every dollar white employees make.

“As a company focused on serving an increasingly diverse world of patients and needing to drive innovation to tackle serious and life-threatening diseases, diversity and inclusion has been—and continues to be—a business imperative,” Highsmith said.

Genentech’s plan divides its goals into three focus areas: encourage belonging, address health inequity—especially in clinical research—and reach out to diverse communities.

The community outreach includes putting its money where its mouth is when it comes to health equity and charitable donations. Last year, Genentech spent $90 million, its highest annual amount to date, on patient support, STEM education and health equity programs.

Genentech’s commitment to diversity and inclusion is also on display in the company’s organizational chart, Highsmith said.

“While diversity teams are typically housed under the human resources umbrella, I report directly to our CEO—a strategic, purposeful and innovative reporting structure designed to enhance the impact of our diversity and inclusion efforts,” she said.

by Sharon Klahr Coey

Source: fiercepharma.com

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.